查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832488

心臟麻痹治療市場（按治療類型、最終用戶、分銷管道和年齡層分類）—全球預測 2025-2032

Cardiac Arrest Treatment Market by Treatment Type, End User, Distribution Channel, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年心臟麻痹治療市場將成長至 485.3 億美元，複合年成長率為 9.35%。

主要市場統計數據
基準年2024年 237.3億美元
預計2025年 259.3億美元
預測年份：2032年 485.3億美元
複合年成長率（%） 9.35%

全面介紹心臟麻痹護理環境，重點介紹臨床緊迫性、創新載體、相關人員角色和系統級實施優先事項

心臟麻痹是急性照護系統中時間最敏感、預後最關鍵的疾病之一，而近期的臨床、技術和政策趨勢正在重塑醫療服務模式。生存取決於整個生存鏈，從快速識別和旁觀者反應，到最佳化的院前干預、先進的院內護理以及復甦後護理。因此，急診醫療服務、醫院、門診中心和居家照護的相關人員正在重新評估臨床路徑、採購優先事項、員工能力和技術投資，以改善神經系統預後並降低可預防死亡率。

機械心肺復甦術、自動去心房顫動、植入式去心房顫動技術、複雜的藥通訊協定、目標體溫管理系統以及日益複雜的監測設備正在匯聚，即時改變臨床決策。這些發展，加上不斷變化的監管預期以及對互通性和資料收集的日益重視，既帶來了機遇，也帶來了營運挑戰。因此，組織領導者必須在短期應對突發事件的準備與長期投資之間取得平衡，以支持韌性、規模化和患者預後顯著改善。

變革性的技術、臨床和操作轉變，重新定義心臟麻痹護理服務、緊急應變整合和可衡量的生存途徑

在設備工程、數位醫療和基於系統的緊急應變設計等技術的推動下，心臟麻痹護理領域正在經歷變革性變革。機械胸外按壓系統正變得更加模組化，易於現場部署，即使在惡劣環境和長途轉運中也能提供持續、高品質的按壓。同時，去心房顫動技術也正向更多樣化的方向發展，包括穿戴式解決方案和更智慧的自動體外心臟去心房顫動，這些去顫器整合了演算法心律分析和對急救人員的即時指導。這些設備層面的改進與二氧化碳測量儀和連續心電圖等監測技術的更緊密整合成相輔相成，為臨床醫生提供有關灌注和心律的即時回饋，從而能夠快速、循證地調整治療方案。

同時，藥物治療方案透過迭代臨床研究不斷完善，目標體溫管理系統也正在進行技術和程序最佳化，以減輕繼發性神經損傷。數位轉型和數據主導實踐正在透過遠端醫療平台和預測分析促進早期預警和調度最佳化，從而縮短回應時間並增強旁觀者、急救人員和接收機構之間的協調。最後，培訓模式也在不斷發展，強調多學科模擬、社區準備和遠端教育。這種轉變正在重新定義成功指標，重點關注互通性、臨床醫生工作流程的完整性以及可證明的患者治療效果，並將其作為採用的核心標準。

對 2025 年美國關稅環境及其對供應鏈彈性、籌資策略、製造本地化和設備准入的影響的累積評估

2025年美國關稅環境為心臟麻痹技術採購、庫存計畫和跨境供應商關係帶來了新的複雜性。影響醫療設備、電子元件和輔助用品的關稅正在對整個供應鏈的成本結構產生直接影響，影響製造商的採購決策，並促使醫院和緊急醫療服務的採購團隊重新評估供應商合約和合約保護措施。由於關稅提高了某些進口組裝和成品的到岸價格，製造商被迫重新評估零件採購，考慮其他生產區域，或在短期內吸收成本的同時，在其他地區尋找效率提升的途徑。

作為應對，一些戰術性行動正在出現。首先，目標商標產品製造商和小型供應商正在加速近岸外包，並擴大國內組裝能，以降低貿易政策波動對其的影響。其次，策略性庫存實踐，包括延長補貨週期和關鍵消耗品的緩衝庫存，正變得越來越普遍，甚至不惜犧牲營運成本。第三，採購團隊正在重新協商總擁有成本條款，將關稅和物流額外費用納入供應商承諾。這些調整不僅僅是財務方面的；它們透過影響哪些產品組合在有限的成本範圍內具有商業性可行性，塑造創新軌跡。

監管和報銷條件與關稅效應相互作用，共同決定淨商業性影響。如果關稅導致醫療設備價格上漲，付款人和公共採購者可能會向製造商施壓，要求其以可證明的臨床效益和長期成本抵消來證明增加的成本是合理的。相反，關稅也為國內製造商和製造外包創造了擴大產能和吸引投資的機會，以確保供應的連續性。最後，政策環境本身是動態的。相關人員必須持續關注關稅調整、醫療豁免和貿易談判，以預測週期中期衝擊並相應地規劃資本投資。從策略角度來看，透過多元化採購、清晰的合約以及產品創新來增強韌性，對於確保關鍵心臟麻痹技術的可及性至關重要。

深入的細分洞察揭示了治療類別、最終用戶偏好、分銷管道和年齡層如何影響招聘、培訓和採購動態

了解細分的細微差別可以揭示不同的治療方式和護理環境如何相互作用，從而影響臨床路徑、採用動態和採購行為。治療類型涵蓋各種設備，從手動和機械 CPR 系統到各種去心房顫動選項，每個類別都提供臨床和操作權衡。機械胸外按壓技術，無論是負荷共享袖帶裝置、活塞驅動系統還是氣動背心設計，都解決了在長時間復甦或運輸過程中維持高品質按壓的挑戰，並且它們的採用往往與系統資源、通訊協定標準化和培訓能力相關。去心房顫動器包括自動體外心臟去心房顫動、植入式心臟整流去顫器和穿戴式去心房顫動解決方案，每個解決方案都需要不同的部署模型和維護方法來滿足不同的用例，從公共場所的突然暈倒到慢性風險管理。

藥物治療仍然是高級心臟生命支持的基石，Amiodarone、腎上腺素和加壓素等藥物在心律管理和血流動力學支持方面發揮著明確的作用。這些治療藥物與設備選擇和體溫管理策略相互作用，而低溫系統（包括血管內和淺表）在旨在保護神經功能的心臟驟停後護理過程中變得至關重要。二氧化碳測量儀儀和心電圖監測儀等監測系統可提供即時調整介入措施所需的臨床回饋，強化了整合設備生態系統的角色。

終端用戶細分進一步協調了需求和服務要求。醫院和急救醫療服務是先進設備和冷卻系統的領先採用者，優先考慮耐用性、服務合約和臨床醫生培訓。門診醫療中心和家庭護理機構越來越重視患者友善穿戴設備，這些設備支援易用性、遠端監控功能和長期風險管理。分銷通路動態也至關重要。雖然透過醫療經銷商和團購進行的傳統線下採購對醫療保健買家仍然至關重要，但線上管道因其便利性和更廣泛的產品可見性，正在為消費者解決方案和可補充耗材拓展。考慮成人、老年人和兒童等年齡層，可以推動臨床通訊協定的差異化、設備尺寸和用藥策略。總而言之，細分可以揭示臨床需求、採購方式和監管要求影響採用時機和投資優先順序的融合點。

美洲、歐洲、中東和非洲以及亞太地區關於採用、監管、製造能力和臨床服務交付的關鍵區域觀點

地區對心臟麻痹技術的監管路徑、服務提供模式和商業策略有重大影響。在美洲，成熟的院前急診系統和大型醫院網路為先進設備、綜合監測技術和實證通訊協定的採用創造了有利條件。北美醫療保健機構優先考慮與電子健康記錄的互通性、急救醫療服務 (EMS) 與醫院之間的協調工作流程以及先進的臨床培訓。同時，採購的複雜性和付款方談判也影響產品組合的選擇和上市後支援的預期。

在歐洲、中東和非洲，我們看到歐盟內部監管協調的混合體，以及其他地區監管架構的比較。高所得的歐洲國家傾向於採用標準化的臨床路徑並投資於公共可及的去心房顫動項目，而中東的醫療保健市場往往追求快速的產能擴張和先進的臨床能力。在非洲部分地區，有限的資源和勞動力短缺推動了對易於維護、堅固耐用且經濟高效的解決方案的需求，這為開發客製化設備和培訓舉措創造了機會。

亞太地區呈現多元化格局，既有醫療體係高度發展的經濟體，也有基礎建設快速發展的經濟體。都市化、急救醫療服務 (EMS) 網路的不斷擴張以及數位醫療的廣泛應用，正在加速亞太地區許多地區的數位化進程。該地區的製造能力也融入全球供應鏈，進而影響採購決策和區域採購慣例。在所有地區，人口老化、心血管危險因子的普遍性以及旁觀者心肺復甦術 (CPR) 訓練率的差異等人口趨勢正在塑造需求強度和特徵。因此，區域策略必須使產品設計、服務模式和臨床參與與當地監管、經濟和勞動力的實際情況一致。

策略性企業行動和產品定位著重於產品組合多樣化、服務擴展、製造業彈性以及領先供應商之間的循證夥伴關係

在心臟麻痹護理領域營運的公司正在推行多項相互重疊的策略重點，以保持成長和臨床相關性。產品組合多元化至關重要，成功的公司將平衡耐用設備、一次性耗材、治療和數位服務的投資，從而為醫院和急救系統提案一體化的價值主張。與急救護理組織、學術中心和契約製造建立策略夥伴關係通常用於加速產品開發、臨床檢驗和銷售擴張。許多領先公司也在擴展其服務範圍，例如培訓、維護和遠端監控，以建立長期合作關係並展示實際成果。

製造佈局和供應鏈架構日益被視為競爭優勢。擁有靈活生產能力和多採購節點的組織更有能力應對關稅衝擊和物流中斷。研發投資持續聚焦於微型化、感測器整合、演算法決策支援以及方便一般急救人員和高級臨床醫生使用。此外，越來越多的公司優先考慮基於結果的證據產生和上市後註冊，以記錄臨床影響並支持報銷談判。策略性舉措涵蓋從增加互補技術的定向收購，到提供院前和復甦後護理捆綁解決方案的聯盟。這些企業行動反映出從交易型設備銷售向強調持續臨床價值的服務導向、循證主導的商業模式的廣泛轉變。

為產業領導者提供可行的策略建議，以增強韌性、加速臨床應用並最佳化醫療環境中的商業模式

產業領導者必須果斷行動，將技術前景轉化為持續的臨床和商業性影響。首先，投資於供應鏈韌性和軟性製造，包括近岸外包、多源採購策略和長期供應商契約，可以減少受政策主導的成本衝擊和物流瓶頸的影響。其次，優先考慮跨裝置和監測系統的互通性和數據標準，可以增強臨床工作流程，並支援院前和院內環境中的結果測量。第三，將臨床證據生成納入產品藍圖，包括真實世界註冊庫和與醫療保健系統的合作試驗，可以加強報銷定位和臨床醫生的採用。

第四，透過配套服務、培訓計畫和基於績效的合約深化與緊急醫療服務和醫院夥伴關係的合作，可以提高持續使用和可衡量成果的可能性。第五，瞄準居家照護和門診市場，採用以使用者為中心的設備設計和遠端監控功能，可以抓住新的需求管道，同時支援照護的連續性。第六，將定價和合約模式與總護理成本核算相結合，包括透過減少神經系統損傷來證明成本抵消，有助於應對付款人的審查。最後，領導者必須制定靈活的監管和上市策略，以預測區域差異並快速實施合規性，確保產品及時推出，並提供適當的臨床醫生教育和技術支援。

調查方法透明度概述了用於得出報告結論的主要研究訪談、臨床證據綜合、監管審查和檢驗步驟

本報告中提出的研究結果和見解是基於一種強調三角測量和透明度的多方法調查方法。主要研究包括對臨床醫生、急救醫療服務 (EMS) 主管、採購負責人和行業高管進行結構化訪談，以了解現場對設備效用、培訓需求和採購挑戰的觀點。此外，我們還對臨床文獻、專業協會指南、監管文件和技術規範進行了廣泛的專家評審，以補充這些定性資訊，確保設備和治療方法分析基於最新證據。此外，我們也參考了上市後監測和臨床註冊數據，以驗證性能聲明並確定醫療機構的採用模式。

我們的分析方法融合了比較產品特徵映射、考慮供應鏈敏感性的情境分析以及專注於近期貿易趨勢的政策影響評估。在整個過程中，我們的研究結果與外部臨床和行業專家進行了反覆檢驗，以減少偏差並確保有效性。我們承認有其限制：快速發展的監管決策和新興的臨床研究可能會改變依證，而特定地區的採購慣例可能會引入差異性，從而需要客製化建議。儘管如此，我們方法的嚴謹性植根於關鍵相關人員、系統性的文獻整合和檢驗循環，為決策者提供了可行的結論和實用指南。

結論整合了技術動力、政策影響和相關人員的責任，以指導心臟麻痹護理的策略規劃和臨床實踐。

心臟麻痹護理領域正處於曲折點，技術創新、政策壓力和不斷發展的服務交付正在匯聚，重新定義臨床實踐。機械去心房顫動技術、強化監測和先進的治療方法，使得在整個生存鏈中實施更一致、數據主導的干涉措施成為可能。然而，這些進步只有在建立部署和維持系統的情況下才能有效。採購慣例、培訓計劃、監管透明度和供應鏈彈性對於將創新轉化為更好的患者預後同樣重要。

展望未來，相關人員必須採取整合策略，平衡臨床證據與營運準備。製造商應優先考慮可互通、服務導向的解決方案和可靠的證據產生。醫療保健提供者和急救醫療系統必須投資於培訓和整合的護理路徑，以將設備功能轉化為可衡量的成果。政策制定者和付款方必須考慮報銷和採購框架，獎勵臨床驗證的技術，同時確保公平的可及性。總而言之，這些相關人員的協同行動將決定新的心臟麻痹治療方法預期如何持續改善存活率和神經功能恢復。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大溫度控制裝置的範圍，提高冷卻效率並實現緊湊設計
  • 整合人工智慧驅動的預測分析，以及早發現高風險患者的心臟麻痹
  • 攜帶式體外膜氧合系統的普及，使得現場快速復甦成為可能
  • 採用雲端基礎的去心房顫動數據平台進行即時性能監控和遠端品質保證
  • 加大對基因治療方法的投資，旨在糾正導致心臟麻痹風險的離子通道疾病
  • 具有智慧型手機定位和使用最佳化功能的複雜公共存取 AED 網路的出現
  • 開發3D列印個人化心臟支持裝置，促進復甦後心臟恢復

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

心臟麻痹治療市場（依治療類型）

  • 心肺復甦設備
    • 荷載分配帶裝置
    • 活塞驅動裝置
    • 氣動背心裝置
  • 去心房顫動
    • 自動體外電擊器
    • 植入式心臟整流去顫器
    • 去心房顫動
  • 藥物治療
    • Amiodarone
    • 腎上腺素
    • 加壓素
  • 低溫系統
    • 血管內冷卻
    • 表面冷卻
  • 監控系統
    • 二氧化碳監測系統
    • 心電圖監測儀

心臟麻痹治療市場（依最終用戶）

  • 門診治療中心
  • 緊急醫療服務
  • 居家照護
  • 醫院

心臟麻痹治療市場（按分銷管道）

  • 離線
  • 線上

第 11 章心臟麻痹治療市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第 12 章心臟麻痹治療市場：按地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章心臟麻痹治療市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

心臟麻痹治療市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • MEDTRONIC PLC
    • ABBOTT LABORATORIES
    • BOSTON SCIENTIFIC CORPORATION
    • KONINKLIJKE PHILIPS NV
    • STRYKER CORPORATION
    • ZOLL MEDICAL CORPORATION
    • BIOTRONIK SE & Co. KG
    • GENERAL ELECTRIC COMPANY
    • NIHON KOHDEN CORPORATION
    • MINDRAY MEDICAL INTERNATIONAL LIMITED
Product Code: MRR-433AB1DC2886

The Cardiac Arrest Treatment Market is projected to grow by USD 48.53 billion at a CAGR of 9.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 23.73 billion
Estimated Year [2025] USD 25.93 billion
Forecast Year [2032] USD 48.53 billion
CAGR (%) 9.35%

Comprehensive introduction to the cardiac arrest treatment landscape highlighting clinical urgency, innovation vectors, stakeholder roles, and system-level implementation priorities

Cardiac arrest represents one of the most time-sensitive and outcome-determinant conditions across acute care systems, and recent years have produced a convergence of clinical, technological, and policy developments that are reshaping how care is delivered. Survivability depends on the entire chain of survival, from rapid recognition and bystander response through optimized prehospital interventions, advanced in-hospital therapies, and post-resuscitation care. As a result, stakeholders across emergency medical services, hospitals, ambulatory centers, and home care are reassessing clinical pathways, procurement priorities, workforce competencies, and technology investments to improve neurological outcomes and reduce preventable mortality.

At the same time, innovation is accelerating along multiple vectors: mechanical CPR solutions, automated and implantable defibrillation technologies, refined pharmacologic protocols, targeted temperature management systems, and increasingly sophisticated monitoring equipment are all converging to change clinical decision-making in real time. These developments are accompanied by evolving regulatory expectations and a growing emphasis on interoperability and data capture, which together create both opportunities and operational challenges. Consequently, organizational leaders must balance near-term readiness for acute events with longer-term investments that support resilience, scale, and measurable improvements in patient outcomes.

Transformative technological, clinical, and operational shifts that are redefining cardiac arrest care delivery, emergency response integration, and measurable survival pathways

The cardiac arrest care landscape is undergoing transformative shifts driven by advances in device engineering, digital health, and systems-based emergency response design. Mechanical chest compression systems have become more modular and field-deployable, enabling consistent high-quality compressions in challenging environments and during prolonged transport. Concurrently, defibrillation technologies are branching into more diverse formats, with wearable solutions and smarter automated external defibrillators that incorporate algorithmic rhythm analysis and real-time guidance for lay responders. These device-level improvements are complemented by tighter integration of monitoring technologies such as capnography and continuous ECG, which provide clinicians immediate feedback on perfusion and rhythm, enabling faster, evidence-based therapeutic adjustments.

In parallel, drug therapy protocols are being refined through iterative clinical research, and targeted temperature management systems have seen both technological and procedural optimization to reduce secondary neurologic injury. Digital transformation and data-driven practices are promoting early-warning and dispatch optimization through telemedicine platforms and predictive analytics, thereby improving response times and coordination between bystanders, EMS, and receiving facilities. Finally, training paradigms are evolving to emphasize multi-disciplinary simulation, community readiness, and remote education, which together create a more resilient emergency response ecosystem. These shifts are redefining the metrics of success-and drawing attention to interoperability, clinician workflow alignment, and demonstrable patient outcomes as the core criteria for adoption.

Cumulative assessment of the 2025 United States tariff environment and its implications for supply chain resilience, procurement strategy, manufacturing localization, and device access

The tariff environment introduced by the United States in 2025 has introduced a new layer of complexity into procurement, inventory planning, and cross-border supplier relationships for cardiac arrest technologies. Tariff actions that affect medical devices, electronic components, and ancillary supplies have immediate implications for cost structures across the supply chain, influencing manufacturer sourcing decisions and prompting procurement teams at hospitals and EMS services to reassess vendor agreements and contractual protections. As tariffs increase the landed cost of certain imported assemblies and finished goods, manufacturers are incentivized to revisit their component sourcing, consider alternate production geographies, or absorb costs in the short term while seeking efficiencies elsewhere.

In response, several tactical behaviors have emerged. First, original equipment manufacturers and smaller suppliers are accelerating nearshoring and expanding domestic assembly capabilities to mitigate exposure to trade policy volatility. Second, strategic inventory practices, including longer replenishment cycles and buffer stock for critical consumables, are more commonly being adopted, albeit at the expense of working capital. Third, procurement teams are renegotiating total-cost-of-ownership clauses to capture duties and logistical surcharges in supplier commitments. These adjustments are not merely financial; they shape innovation trajectories by influencing which product configurations are commercially viable within constrained cost envelopes.

Regulatory and reimbursement landscapes interact with tariff effects to determine net commercial impact. Where tariffs increase device prices, payers and public purchasers may pressure manufacturers to justify cost increases through demonstrable clinical benefit and long-term cost offsets. Conversely, tariffs have created opportunities for domestic manufacturers and contract manufacturers to expand capacity, attracting investment aimed at ensuring continuity of supply. Finally, the policy environment itself is dynamic: stakeholders must continuously monitor tariff adjustments, exemptions for medical goods, and trade negotiations to anticipate mid-cycle shocks and plan capital investments accordingly. From a strategic perspective, resilience through diversified sourcing and contractual clarity has become as essential as product innovation in safeguarding access to critical cardiac arrest technologies.

Deep segmentation insights revealing how treatment modality categories, end-user settings, distribution channels, and age cohorts collectively shape adoption, training, and procurement dynamics

A nuanced understanding of segmentation reveals how different treatment modalities and care settings interact to shape clinical pathways, adoption dynamics, and procurement behavior. Within treatment types, devices range from manual and mechanical CPR systems to a spectrum of defibrillation options, and each category presents specific clinical and operational trade-offs. Mechanical chest compression technologies-whether load-distributing band devices, piston-driven systems, or pneumatic vest designs-address the challenge of sustained high-quality compressions in prolonged resuscitation or transport, and adoption tends to correlate with system resources, protocol standardization, and training capacity. Defibrillation spans automated external defibrillators, implantable cardioverter devices, and wearable cardioverter solutions; each fulfills distinct use cases from public-access sudden collapse to chronic risk management, requiring different deployment models and maintenance approaches.

Drug therapies remain a cornerstone of advanced cardiac life support, with agents such as amiodarone, epinephrine, and vasopressin occupying defined roles in rhythm management and hemodynamic support. These therapeutics interplay with device choices and temperature management strategies, with hypothermia systems-both endovascular and surface cooling-becoming integral to post-arrest care pathways that seek to preserve neurologic function. Monitoring systems such as capnography units and ECG monitors provide the clinical feedback necessary to titrate interventions in real time, reinforcing the role of integrated device ecosystems.

End-user segmentation further modulates demand and service requirements. Hospitals and emergency medical services are primary adopters of advanced devices and cooling systems and prioritize durability, service contracts, and clinician training. Ambulatory care centers and home care settings increasingly emphasize ease of use, remote monitoring capabilities, and patient-friendly wearables that support long-term risk management. Distribution channel dynamics are also pivotal: traditional offline procurement through medical distributors and group purchasing remains essential for institutional buyers, while online channels are growing for consumer-facing solutions and replenishable supplies due to convenience and broader product visibility. Age-group considerations-adult, geriatric, and pediatric-drive clinical protocol differentiation, device sizing, and drug dosing strategies, with pediatric applications often requiring specialized training and device adaptations. Taken together, segmentation illuminates where clinical need, procurement style, and regulatory obligations converge to influence adoption timing and investment priorities.

Key regional perspectives on adoption, regulation, manufacturing capacity, and clinical service delivery across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Geography materially influences regulatory pathways, service delivery models, and commercial strategies for cardiac arrest treatment technologies. In the Americas, established prehospital systems and large hospital networks create favorable conditions for advanced devices, integration of monitoring technologies, and adoption of evidence-based protocols. North American institutions frequently emphasize interoperability with electronic health records, coordinated EMS-hospital workflows, and high levels of clinical training. In parallel, procurement complexity and payer negotiations shape product configuration choices and post-market support expectations.

Across Europe, Middle East & Africa, regulatory harmonization within the European Union and contrasting regulatory architectures elsewhere create a mixed landscape. High-income European countries tend to adopt standardized clinical pathways and invest in public access defibrillation programs, while Middle Eastern healthcare markets often pursue rapid capacity expansion and advanced clinical capabilities. In parts of Africa, constrained resources and workforce shortages demand solutions that are low-maintenance, rugged, and cost-effective, creating opportunities for tailored devices and training initiatives.

The Asia-Pacific region exhibits substantial heterogeneity, driven by a mix of highly developed healthcare systems in some economies and rapidly upgrading infrastructure in others. Urbanization, expanding EMS networks, and digital health penetration are accelerating adoption in many parts of Asia-Pacific. Manufacturing capacity in the region also feeds global supply chains, which in turn affects sourcing decisions and regional procurement practices. Across all regions, demographic trends such as aging populations, the prevalence of cardiovascular risk factors, and differences in bystander CPR training rates shape the intensity and character of demand. Consequently, regional strategies must align product design, service models, and clinical engagement to local regulatory, economic, and workforce realities.

Strategic corporate behaviors and product positioning emphasizing portfolio diversification, service expansion, manufacturing resilience, and evidence-driven partnerships among leading providers

Companies operating in the cardiac arrest treatment space are pursuing several overlapping strategic priorities to sustain growth and clinical relevance. Portfolio diversification is central: successful firms balance investments across durable devices, disposable consumables, therapeutics, and digital services to create integrated value propositions for hospitals and EMS systems. Strategic partnerships with emergency care providers, academic centers, and contract manufacturers are commonly used to accelerate product development, clinical validation, and distribution reach. Many leading firms are also expanding service offerings-training, maintenance, and remote monitoring-to lock in long-term relationships and demonstrate real-world outcomes.

Manufacturing footprint and supply chain architecture are increasingly seen as competitive differentiators. Organizations with flexible production capabilities and multiple sourcing nodes are better positioned to absorb tariff shocks and logistic disruptions. Research and development investments continue to focus on miniaturization, sensor integration, algorithmic decision support, and ease of use for both lay rescuers and advanced clinicians. In addition, a growing number of companies are prioritizing outcomes-based evidence generation and post-market registries to document clinical impact and support reimbursement discussions. Strategic moves range from targeted acquisitions that add complementary technologies to collaborations that deliver bundled solutions for prehospital and post-resuscitation care. These corporate behaviors reflect a broader shift from transactional device sales toward service-oriented, evidence-driven commercial models that emphasize sustained clinical value.

Actionable strategic recommendations enabling industry leaders to strengthen resilience, accelerate clinical adoption, and optimize commercial models across care settings

Industry leaders must act decisively to translate technological promise into sustained clinical and commercial impact. First, investing in supply chain resilience and flexible manufacturing-whether through nearshoring, multi-sourcing strategies, or long-term supplier agreements-will reduce exposure to policy-driven cost shocks and logistical bottlenecks. Second, prioritizing interoperability and data standards across devices and monitoring systems will enhance clinical workflows and support outcome measurement across prehospital and in-hospital settings. Third, embedding clinical evidence generation into product roadmaps, including real-world registries and collaborative trials with healthcare systems, will strengthen reimbursement positioning and clinician adoption.

Fourth, deepening partnerships with EMS services and hospital networks through bundled service offerings, training programs, and performance-based contracts will increase the likelihood of sustained use and measurable outcomes. Fifth, targeting home care and ambulatory markets with user-centered device designs and remote-monitoring capabilities can capture new demand pathways while supporting continuity of care. Sixth, aligning pricing and contracting models with total-cost-of-care narratives-including demonstrating cost offsets from reduced neurologic disability-will help address payer scrutiny. Finally, leaders should develop agile regulatory and market-access strategies that anticipate regional variances and quickly operationalize compliance, ensuring that product introductions are timely and supported by appropriate clinician education and technical support.

Methodological transparency outlining primary research interviews, clinical evidence synthesis, regulatory review, and validation steps used to derive the report's conclusions

The findings and insights presented in this report are based on a multi-method research approach that emphasizes triangulation and transparency. Primary research included structured interviews with clinicians, EMS directors, procurement officers, and industry executives to capture frontline perspectives on device utility, training needs, and procurement challenges. These qualitative inputs were supplemented by an extensive review of peer-reviewed clinical literature, guidelines from professional societies, regulatory filings, and technical specifications to ground device and therapeutics analysis in contemporary evidence. Where available, post-market surveillance data and clinical registries were consulted to validate performance claims and to contextualize adoption patterns across care settings.

Analytical methodologies incorporated comparative product feature mapping, scenario analysis to examine supply chain sensitivities, and policy impact assessment focused on recent trade developments. Throughout the process, findings were iteratively validated with external clinical and industry experts to reduce bias and ensure relevance. Limitations are acknowledged: rapidly evolving regulatory decisions and emergent clinical studies can shift the evidence base, and localized procurement practices may create heterogeneity that requires customization of recommendations. Nevertheless, the methodological rigor-rooted in primary stakeholder engagement, systematic literature synthesis, and validation loops-supports actionable conclusions and pragmatic guidance for decision-makers.

Integrated conclusions synthesizing technological momentum, policy influences, and stakeholder responsibilities to guide strategic planning and clinical practice in cardiac arrest treatment

The cardiac arrest treatment landscape is at an inflection point where technological innovation, policy pressures, and service delivery evolution are converging to redefine clinical practice. Mechanical and defibrillation technologies, enhanced monitoring, and refined therapeutic approaches are collectively enabling more consistent, data-driven interventions across the entire chain of survival. Yet, these advancements are only as effective as the systems that deploy and sustain them; procurement practices, training programs, regulatory clarity, and supply chain resilience are equally critical to converting innovation into improved patient outcomes.

Looking forward, stakeholders must adopt integrated strategies that marry clinical evidence with operational readiness. Manufacturers should prioritize interoperable, service-oriented solutions and robust evidence generation. Providers and EMS systems will need to invest in training and integrated care pathways that translate device capabilities into measurable outcomes. Policymakers and payers must consider reimbursement and procurement frameworks that incentivize clinically proven technologies while ensuring equitable access. Taken together, coordinated action across these constituencies will determine the pace at which the promise of new cardiac arrest treatments produces durable improvements in survival and neurologic recovery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of targeted temperature management devices with improved cooling efficiency and compact designs
  • 5.2. Integration of AI-driven predictive analytics for early detection of sudden cardiac arrest in high-risk patients
  • 5.3. Surge in portable extracorporeal membrane oxygenation systems enabling rapid field-based resuscitation efforts
  • 5.4. Adoption of cloud-based defibrillator data platforms for real-time performance monitoring and remote quality assurance
  • 5.5. Growing investment in gene therapy approaches aiming to correct channelopathies underlying sudden cardiac arrest risk
  • 5.6. Emergence of advanced public access AED networks with smartphone-enabled location and usage optimization
  • 5.7. Development of 3D-printed personalized cardiac support devices for enhanced post-resuscitation cardiac function recovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Arrest Treatment Market, by Treatment Type

  • 8.1. Cpr Devices
    • 8.1.1. Load Distributing Band Device
    • 8.1.2. Piston Driven Device
    • 8.1.3. Pneumatic Vest Device
  • 8.2. Defibrillator Devices
    • 8.2.1. Automated External Defibrillator
    • 8.2.2. Implantable Cardioverter Defibrillator
    • 8.2.3. Wearable Cardioverter Defibrillator
  • 8.3. Drug Therapies
    • 8.3.1. Amiodarone
    • 8.3.2. Epinephrine
    • 8.3.3. Vasopressin
  • 8.4. Hypothermia Systems
    • 8.4.1. Endovascular Cooling
    • 8.4.2. Surface Cooling
  • 8.5. Monitoring Systems
    • 8.5.1. Capnography Systems
    • 8.5.2. Ecg Monitors

9. Cardiac Arrest Treatment Market, by End User

  • 9.1. Ambulatory Care Center
  • 9.2. Emergency Medical Services
  • 9.3. Home Care
  • 9.4. Hospital

10. Cardiac Arrest Treatment Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Cardiac Arrest Treatment Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Cardiac Arrest Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cardiac Arrest Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiac Arrest Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. MEDTRONIC PLC
    • 15.3.2. ABBOTT LABORATORIES
    • 15.3.3. BOSTON SCIENTIFIC CORPORATION
    • 15.3.4. KONINKLIJKE PHILIPS N.V.
    • 15.3.5. STRYKER CORPORATION
    • 15.3.6. ZOLL MEDICAL CORPORATION
    • 15.3.7. BIOTRONIK SE & Co. KG
    • 15.3.8. GENERAL ELECTRIC COMPANY
    • 15.3.9. NIHON KOHDEN CORPORATION
    • 15.3.10. MINDRAY MEDICAL INTERNATIONAL LIMITED

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CARDIAC ARREST TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CARDIAC ARREST TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC ARREST TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY LOAD DISTRIBUTING BAND DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PISTON DRIVEN DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PNEUMATIC VEST DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AUTOMATED EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY WEARABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMIODARONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMIODARONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMIODARONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMIODARONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMIODARONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMIODARONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EPINEPHRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EPINEPHRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EPINEPHRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EPINEPHRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EPINEPHRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EPINEPHRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY VASOPRESSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY VASOPRESSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY VASOPRESSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY VASOPRESSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY VASOPRESSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ENDOVASCULAR COOLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ENDOVASCULAR COOLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ENDOVASCULAR COOLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ENDOVASCULAR COOLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ENDOVASCULAR COOLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ENDOVASCULAR COOLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY SURFACE COOLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY SURFACE COOLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY SURFACE COOLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY SURFACE COOLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY SURFACE COOLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY SURFACE COOLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY CAPNOGRAPHY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ECG MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY EMERGENCY MEDICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC ARREST TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CARDIAC ARREST TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY CPR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY DEFIBRILLATOR DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY DRUG THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY HYPOTHERMIA SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY MONITORING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CARDIAC ARREST TREATMENT MARKET SIZE, BY END USE